Broad Range of Technologies and Services for Pharmaceutical Product Lifecycle
Saltigo at CPhI Japan 2010
Tokyo - Saltigo GmbH, a wholly owned subsidiary of German specialty chemicals company LANXESS, will showcase what has made it a leader in custom synthesis at CPhI Japan 2010 from April 21 to 23, 2010. The company will exhibit its vast range of technologies and services that provide support throughout the entire lifecycle of pharmaceuticals, from initial process development and production of investigational new drug (IND) ingredients, right up to large-scale production of active pharmaceutical ingredients (APIs) and intermediates. At this ninth edition in Japan of the CPhI (International Convention on Pharmaceutical Ingredients and Intermediates), Saltigo will be at booth M-17 in East Hall 5 and 6 of Tokyo Big Sight.
The CPhI Japan 2010 international trade fair will feature approximately 450 manufacturers of pharmaceutical ingredients and intermediates from around the world. The biggest annual event in Japan´s pharmaceutical industry, CPhI Japan draws high interest and participation from major players, researchers, and other concerned parties in the field. Saltigo will showcase the wide range of technologies and services it offers to support almost the entire lifecycle of customers´ pharmaceutical products. The booth will focus on the services offered by Saltigo´s Redmond, Washington site in the USA, which went into full-scale operation last year. The LANXESS subsidiary is also highlighting the large-scale production of APIs and intermediates at the Leverkusen plant in Germany.
The production site in Redmond has the speed and flexibility critical for the fast track to support of projects in the early clinical trial stages. Services ranging from initial process development and sample synthesis to the production of IND ingredients, are complimented by the ability to provide regulatory registration support for FDA approval. In Japan, Saltigo has built a solid business foundation in markets related to the agrochemical, pharmaceutical, and specialty chemicals industries, particularly in segments supporting the life sciences industry.
Saltigo GmbH is a leading supplier in the field of custom synthesis, offering complete, tailor-made solutions for customers both in the crop protection and pharmaceuticals segments and in various non-life-science industries. The company is part of the LANXESS AG specialty chemicals group and belongs to the Advanced Intermediates segment, which generated sales of EUR 1,140 million in fiscal 2009. Saltigo, headquartered in Langenfeld with production facilities in Leverkusen and Dormagen, employs around 1,400 staff worldwide. LANXESS Corporation operates a site for Saltigo in Redmond (Washington, United States).
Detailed information about the company can be found on the internet at www.saltigo.com.
Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by LANXESS AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever
to update these forward-looking statements or to conform them to future events or developments.
